Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Ariad Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Ariad Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ariad Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ariad Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ariad Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Ariad Pharmaceuticals, Inc.'s pipeline products

Reason to Buy

- Evaluate Ariad Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ariad Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ariad Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ariad Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ariad Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Ariad Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Ariad Pharmaceuticals, Inc. Snapshot 5
Ariad Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Ariad Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Ariad Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Out-Licensed Products 11
Out-Licensed Products/Combination Treatment Modalities 12
Ariad Pharmaceuticals, Inc. - Pipeline Products Glance 13
Ariad Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Ariad Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Ariad Pharmaceuticals, Inc. - Drug Profiles 15
brigatinib 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
ponatinib hydrochloride 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
(ponatinib hydrochloride + ridaforolimus) 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
AP-32788 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Ariad Pharmaceuticals, Inc. - Pipeline Analysis 20
Ariad Pharmaceuticals, Inc. - Pipeline Products by Target 20
Ariad Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 21
Ariad Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 22
Ariad Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 23
Ariad Pharmaceuticals, Inc. - Recent Pipeline Updates 24
Ariad Pharmaceuticals, Inc. - Dormant Projects 40
Ariad Pharmaceuticals, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
AP-23451 41
ponatinib hydrochloride 41
Ariad Pharmaceuticals, Inc. - Company Statement 42
Ariad Pharmaceuticals, Inc. - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables

Ariad Pharmaceuticals, Inc., Key Information 5
Ariad Pharmaceuticals, Inc., Key Facts 5
Ariad Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
Ariad Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Ariad Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Ariad Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Ariad Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 11
Ariad Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 12
Ariad Pharmaceuticals, Inc. - Phase II, 2015 13
Ariad Pharmaceuticals, Inc. - Preclinical, 2015 14
Ariad Pharmaceuticals, Inc. - Pipeline by Target, 2015 20
Ariad Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 21
Ariad Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 22
Ariad Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 23
Ariad Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 24
Ariad Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 40
Ariad Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 41
Ariad Pharmaceuticals, Inc., Subsidiaries 44